# US 2010/0168204 A1 · Therapeutic uses of inhibitors of RTP801L

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168204 A1
- Document ID: US20100168204A1
- Status: Published application
- Kind: A1
- Application number: 12/589,972
- Filed: 2009-10-29
- Published: 2010-07-01
- Earliest claimed: 2006-06-09
- Assignees: Quark Pharmaceuticals, Inc.
- Inventors: Elena Feinstein; Igor Mett
- Web page: https://patentgrep.com/patent/US20100168204A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/00: Drugs for disorders of the senses
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/321: 2'-O-R Modification
- C12N 2320/31: Combination therapy
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases respiratory conditions and hearing disorders based upon inhibition of the RTP801L gene and/or protein.

## Claims

### Claim 1

(canceled)

### Claim 2

A compound having the structure:
wherein alternating ribonucleotides in the antisense and the sense strands are modified to result in a 2′-O-methyl modification in the sugar residue of the ribonucleotides;
wherein the ribonucleotides at the 5′ and 3′ termini of the antisense strand are modified to result in the 2′-O-methyl modification; wherein the ribonucleotides at the 5′ and 3′ termini of the sense strand are unmodified; wherein at least one of the antisense and the sense strands is phosphorylated at the 3′ termini; and wherein each of the antisense strand and the sense strand is 19-23 nucleotides in length.

### Claim at position 3

3-13. (canceled)

### Claim 14 (depends on 2)

A composition comprising the compound of claim 2 and a pharmaceutically acceptable excipient.

### Claim at position 5

15-25. (canceled)

### Claim 26

A compound having the structure:
wherein alternating ribonucleotides in the antisense and the sense strands are modified to result in a 2′-O-methyl modification in the sugar residue of the ribonucleotides;
wherein the ribonucleotides at the 5′ and 3′ termini of the antisense strand are modified to result in the 2′-O-methyl modification; wherein the ribonucleotides at the 5′ and 3′ termini of the sense strand are unmodified; wherein at least one of the antisense and the sense strands is phosphorylated at the 3′ termini; and wherein each of the antisense strand and the sense strand is 19-23 nucleotides in length.

### Claim at position 7

27-37. (canceled)

### Claim 38 (depends on 26)

A composition comprising the compound of claim 26 and a pharmaceutically acceptable excipient.

### Claim at position 9

39-48. (canceled)

### Claim 49 (depends on 2)

The compound of claim 2, wherein each of the antisense strand and the sense strand is 19 nucleotides in length.

### Claim 50 (depends on 26)

The compound of claim 26, wherein each of the antisense strand and the sense strand is 19 nucleotides in length.

### Claim 51

A compound having the structure:
wherein each of the antisense strand and the sense strand is 19-23 nucleotides in length.

### Claim 52

A compound having the structure:
wherein each of the antisense strand and the sense strand is 19-23 nucleotides in length.
